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Abstract
Background: Breast cancer chemoprevention can reduce breast cancer incidence in high-risk women; however,
chemoprevention is underutilized in the primary care setting. We conducted a pilot study of decision support tools
among high-risk women and their primary care providers (PCPs).
Methods: The intervention included a decision aid (DA) for high-risk women, RealRisks, and a provider-centered tool,
Breast Cancer Risk Navigation (BNAV). Patients completed validated surveys at baseline, after RealRisks and after their
PCP clinical encounter or at 6-months. Referral for high-risk consultation and chemoprevention uptake were assessed
via the electronic health record. The primary endpoint was accuracy of breast cancer risk perception at 6-months.
Results: Among 40 evaluable high-risk women, median age was 64.5 years and median 5-year breast cancer risk was
2.19%. After exposure to RealRisks, patients demonstrated an improvement in accurate breast cancer risk perceptions
(p = 0.02), an increase in chemoprevention knowledge (p < 0.01), and 24% expressed interest in taking chemoprevention.
Three women had a high-risk referral, and no one initiated chemoprevention. Decisional conflict significantly increased
from after exposure to RealRisks to after their clinical encounter or at 6-months (p < 0.01). Accurate breast cancer risk
perceptions improved and was sustained at 6-months or after clinical encounters. We discuss the side effect profile of
chemoprevention and the care pathway when RealRisks was introduced to understand why patients experienced
increased decision conflict.
Conclusion: Future interventions should carefully link the use of a DA more proximally to the clinical encounter,
investigate timed measurements of decision conflict and improve risk communication, shared decision making, and
chemoprevention education for PCPs. Additional work remains to better understand the impact of decision aids targeting
both patients and providers.
Trial registration: ClinicalTrials.gov Identifier: NCT02954900 November 4, 2016 Retrospectively registered.
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Background
Breast cancer is the most common cancer among women
in the United States, with an estimated 1 in 8 women de-
veloping invasive breast cancer during her lifetime [1].
More than 252,700 new cases and 40,610 deaths due to
breast cancer are expected to occur among U.S. women in
2017 [2]. Women with a 5-year invasive breast cancer risk
greater than 1.67% or a lifetime risk greater than 20%
based upon the Gail model [3] have the option of taking a
chemopreventive medication. Chemoprevention with se-
lective estrogen receptor modulators (SERMs) and aroma-
tase inhibitors (AIs) has been shown to reduce invasive
breast cancer risk by up to 50–65% among high-risk
women in randomized controlled trials [4–7]. Grounded
in strong evidence, the U.S. Preventive Services Task Force
(USPSTF), National Comprehensive Cancer Network
(NCCN), American Society for Clinical Oncology
(ASCO), and the National Institute for Health and Care
Excellence (NICE) recommend that clinicians discuss pre-
ventive therapy with high-risk women [8–11]. However,
uptake of SERMs or AIs for the prevention of breast can-
cer is extremely low [12]. In a meta-analysis of therapeutic
agent uptake to prevent breast cancer among women at
increased risk, Smith et al. found that uptake was 25.2%
among women screened for clinical trials, but only 8.7%
(95% CI, 6.8–10.9) in non-trial settings [13].
Decision aids can help to improve communication be-
tween providers and patients, and can assist patients clar-
ify how important the potential benefits and harms are to
them. However, studies that examined the effect of deci-
sion aids on SERM use found that while knowledge about
risks and benefits increased, decisions were rarely influ-
enced. Guide to Decide, a decision aid that informed
high-risk postmenopausal women about potential chemo-
prevention benefits and side effects resulted in no tamoxi-
fen uptake and only 0.5% uptake of raloxifene [14]. The
Ready, Set, GO GAIL! study involved PCPs using the Gail
model to screen more than 5700 women [15]. Although
868 (15.2%) women were classified as high-risk for breast
cancer, only 14.7% were referred for risk counseling, 6.4%
attended the consultation, and 2% started chemopreven-
tion. The BreastCARE randomized controlled trial re-
vealed that more women were referred for high-risk
consultation in the intervention group compared to
controls, however there was limited communication about
chemoprevention documented in the medical record [16].
The literature is surprisingly scant on decision aids tar-
geting both patients and providers [17], and most studies
on chemoprevention decision-making have been based on
hypothetical scenarios to evaluate levels of interest, which
may ineffectively predict actual uptake [12]. Studies confirm
the importance of the primary care provider recommenda-
tion for the decision to take a SERM for breast cancer risk
reduction [18–20]. However, this recommendation was
more likely to be followed when SERM use discussions as-
sess patient attitudes toward medication and relate to those
when discussing chemoprevention options to make the
information relevant to the patients [18]. Since breast
cancer chemoprevention is not generally diffused in the
primary care setting, more effective tools are needed to
inform both providers and patients about the risks and
benefits of SERMs and AIs, help them to identify available
options and deliberate those options in light of patients
values and preferences.
In this paper, we report results of a pilot study con-
ducted to examine the efficacy of two decision support
tools, the RealRisks decision aid (DA) for patients and
the Breast cancer risk NAVigation (BNAV) decision
support tool for primary care providers (PCPs) [21]. Pro-
viders received BNAV decision support at the time their
patient completed RealRisks, thus the tools when
integrated into clinical workflow were intended to com-
plement one another. We sought to determine whether
our decision support tools increase patient’s accuracy of
breast cancer risk perceptions, and breast cancer and
chemoprevention knowledge. We also sought to identify
referrals for consultation at a high-risk breast clinic, and
chemoprevention uptake among women at high risk for
breast cancer post intervention.
Methods
Study population and eligibility criteria
Women (N = 19,026) presented for screening mammog-
raphy at Columbia University Medical Center (CUMC)
in New York, NY between 2014 and 2016 (Fig. 1) [22].
Among them, 3743 (19.7%) were approached for enroll-
ment into the Know Your Risk: Assessment at Screening
(KYRAS) for breast cancer study, and 3077 (82.2%) con-
sented and completed a baseline survey on demograph-
ics and breast cancer risk factors. Of the 3077, 511
(16.6%) women were identified as high-risk for breast
cancer according to the Gail model. These high-risk
women were informed of their breast cancer risk status
and given a brochure to the CUMC breast clinic for a
high-risk consultation. A subset of participants (N = 50)
from this larger study was recruited into a single-arm
pilot intervention study of the chemoprevention decision
support tools. Eligibility criteria for the pilot included
the following: 1) women, age 35–75 years; 2) 5-year inva-
sive breast cancer risk ≥1.67% based upon the Gail
model [3]; 3) having a primary care provider (PCP) at
CUMC; 4) English or Spanish-speaking. Those with any
history of breast cancer or with current or prior use of a
selective estrogen receptor modulator (SERM) or aroma-
tase inhibitor (AI) for breast cancer risk reduction were
excluded. Having a PCP at CUMC was an inclusion cri-
teria to ensure that both patient and provider would
have access to the decision support tools and we could
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access the electronic health record at CUMC. Providers
from primary care clinics at CUMC were invited to par-
ticipate if they had an identified patient eligible for
breast cancer chemoprevention. This study was ap-
proved by the institutional review board at CUMC and
registered at clinicaltrials.gov (NCT02954900).
Study interventions
RealRisks is a web-based patient-centered decision aid
(DA) designed to increase the following: 1) accurate breast
cancer risk perceptions; 2) breast cancer and chemopre-
vention knowledge; and 3) self-efficacy to engage in a
collaborative dialogue about breast cancer risk and che-
moprevention decisions (Fig. 2). We designed RealRisks
by involving both patients and providers in multiple
design sessions and usability studies to arrive at guiding
principles that focused on the following: 1) options for
providing information of breast cancer risk and chemo-
prevention, 2) “interactive games” to communicate breast
cancer risk, and 3) patient preference elicitation to weigh
the risks and benefits of SERMs and AIs (Fig. 2). An early
prototype was evaluated in focus groups among women of
various ethnicities from New York City. In this evaluation,
accuracy of breast cancer risk perception (perceived
minus actual breast cancer risk according to the Gail
model [3]) significantly improved after interacting with
RealRisks, even in the subgroup of women with low
numeracy [23]. After the initial prototype was developed,
we conducted usability studies with English- and Spanish-
speaking women to determine how they navigated, en-
gaged with and understood the information in RealRisks
[21]. Using surveys, think-aloud protocols, and subject
recordings, we identified several themes relating to the us-
ability of RealRisks, specifically in the content, ease of use,
Fig. 1 Consort Diagram
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and navigability of the application. By conducting studies
in two languages with a diverse multi-ethnic population,
we were able to implement interface changes to make
RealRisks accessible to users with varying levels of health
literacy and acculturation.
RealRisks includes the option to view the material in a
text-heavy, or “information dense,” format or in an “in-
formation light” format that primarily uses pictures. The
DA also has an audio option and Spanish translations.
The educational modules include: 1) Breast cancer risk
(breast cancer risk factors, calculation of personal breast
cancer risk according to the Gail model, interactive
games on risk communication); and 2) Chemopreven-
tion (what is chemoprevention, risks and benefits of
SERMs and AIs for chemoprevention, preference elicit-
ation of chemoprevention). Through the RealRisks DA,
Fig. 2 Screenshots of RealRisks, patient-centered decision aid: (a) Graphic novel-style narrative; (b) Interactive game to communicate breast cancer risk;
(c) Preference elicitation about the risks and benefits of chemoprevention
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we collect information on breast cancer risk factors to cal-
culate a patient’s Gail risk score. We also collect factors
that influence the decision making about chemopreven-
tion through the preference elicitation game. RealRisks
generates an action plan for patients summarizing their
personalized breast cancer risk profile and preferences for
chemoprevention. A provider view of the action plan,
which is much shorter in length and designed to be
actionable, is also made available to the provider through
BNAV.
The provider-facing BNAV tool (Fig. 3) uses a two-
pronged strategy to improve knowledge among health-
care providers about breast cancer risk assessment and
chemoprevention. After patients complete RealRisks,
their providers receive the tailored action plan via secure
health messaging and are offered access the web-based
BNAV toolbox. Based on the Theory of Planned Behav-
ior [24], the toolbox contains a collection of information
and resources that includes: 1) up-to-date guidelines and
interactive educational presentations (attitudes); 2) video
testimonials from experts in the field and a social com-
ponent that enables a provider to compare his or her
performance against aggregate, anonymous data of his
or her peers (subjective norm); and 3) a repository of
their patients’ breast cancer risk, together with the ac-
tion plans generated by the patients’ interactions with
RealRisks (perceived behavioral control). The BNAV
chemoprevention module includes resources on breast
cancer risk assessment, benefits and risks of chemopre-
vention, and how to manage the side effects of SERMs
and AIs. Over time, other modules have been integrated
into RealRisks (genetic testing for hereditary breast and
ovarian cancer syndrome (HBOC), screening recommen-
dations and guidelines, and risky health behaviors and
lifestyle modification) and BNAV (genetic testing for
HBOC, screening recommendations and guidelines, and
patient-centered care), which allow providers to self-dir-
ect viewing resources outside of the clinical encounter.
Each module takes about 10–20 min to view and can be
completed during multiple sittings. To evaluate BNAV,
individual interviews were conducted with 10 PCPs [25].
We found that few providers routinely used breast can-
cer risk calculators in their practice and they expressed
concerns about the added burden of incorporating these
tools into the clinic visit and being unfamiliar with
chemoprevention.
Outcome measures and data collection
High-risk women completed self-administered question-
naires at baseline, immediately after completing RealRisks,
and 6months after baseline or after the clinical encounter
with their PCP. Health literacy, subjective and objective
numeracy, and acculturation were assessed at base-
line using brief validated measures of each construct
[26, 27]. Breast cancer and chemoprevention knowledge
was assessed using a 13-item scale, with adequate know-
ledge defined as at least 50% correct responses [28]. A par-
ticipant’s confidence in communicating with her PCP was
measured as an average of three items (range: 0–100%)
[29]. Breast cancer risk perception was assessed by four
items of absolute estimate, comparative risk assessed
on a 3-point Likert scale, and numeric 5-year and
lifetime risk on a scale of 0 to 100% [30]. Breast can-
cer worry was assessed using responses to two ques-
tions on a 7-point Likert scale [31, 32]. Self-efficacy
was measured as an average of 5 items to assess per-
ceived confidence in making a choice (range: 0–100%)
[33]. Decision conflict was measured using the low
literacy version of the Decision Conflict Scale (DCS)
after exposure to RealRisks and at 6 months or after
the PCP clinical encounter. The total score was calcu-
lated by averaging the 10 individual item scores so
that higher scores indicated higher decisional conflict
(range: 0–100) [33]. Scores lower than 25 on the scale
are associated with implementing decisions whereas
scores greater than 37.5 indicate high decision con-
flict, which is characterized by decision delay and/or
uncertainty. Subscores of the scale that focus on
factors contributing to uncertainty (e.g., feeling uncer-
tain, uninformed, unclear about values, and unsup-
ported in decision-making) were also reported on a
range from 0 to 100 [33]. Behavioral intent for che-
moprevention was assessed as previously described
[14]. Referral to the high-risk breast clinic and che-
moprevention uptake were assessed at 6 months via
the electronic health record (EHR).
Statistical analysis
Our primary endpoint was accuracy of perceived breast
cancer risk, defined as perceived lifetime risk within
±10% of actual lifetime risk according to the Gail model,
at 6 months compared to baseline. The 10% range on ei-
ther side of the Gail model risk estimate has been com-
monly used to provide a reasonable margin within
which responses are labeled as accurate [34–37].McNe-
mar’s test was used to compare accurate breast cancer
risk perception and adequate breast cancer and chemo-
prevention knowledge at baseline and follow-up. Paired
t-tests were utilized to assess changes in continuous
measures of differences in perceived and actual lifetime
breast cancer risk, breast cancer and chemoprevention
knowledge, breast cancer worry, self-efficacy, and deci-
sion conflict from baseline to post-RealRisks, from base-
line to post-clinical encounter or 6 months, and from
post-RealRisks to post-clinical encounter or 6 months.
All analyses were conducted using SAS version 9.4
(Cary, NC) and a p-value < 0.05 was considered to be
statistically significant.
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Fig. 3 Screenshots of BNAV (Breast cancer risk NAVigation) provider-centered tool: (a) Slide presentations; (b) Link to download references
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Results
Participants
Table 1 summarizes the baseline characteristics of the
forty women who met all eligibility criteria and completed
the baseline survey. The majority (95%) were postmeno-
pausal women with a median age of 64.5 years (range, 49–
72 years). Our sample was racially and ethnically diverse
with 42.5% Hispanics, 40.0% non-Hispanic white, 12.5%
non-Hispanic black and 5.0% Asian or other. The mean
5-year invasive breast cancer risk, based on the Gail
model, was 2.38 ± 0.81%. Thirty-five percent reported hav-
ing benign breast disease and half of them had a
first-degree family history of breast cancer. Compared to
non-Hispanic women, Hispanics were less educated and
had lower acculturation, health literacy, and numeracy.
Patient reported outcomes at baseline, post-intervention
and 6months.
Table 2 summarizes the patient-reported outcomes at
baseline, post-intervention (RealRisks) and at 6months or
after the clinical encounter with their primary care pro-
vider (PCP). At baseline, the majority of patients (75%)
overestimated their perceived risk of breast cancer. Accur-
ate breast cancer risk perceptions increased from 38% at
baseline to 63% at 6months (p = 0.03). The mean differ-
ence between perceived and actual lifetime breast cancer
risk according to the Gail model decreased from 23.7%
(SD 24.7) at baseline to 12.1% (SD 18.1) post-RealRisks
(p = 0.01). After exposure to RealRisks, there was no sig-
nificant change in breast cancer knowledge; however,
mean chemoprevention knowledge scores significantly im-
proved from baseline to follow-up, but this difference di-
minished over time (0.71 at baseline, 3.69 post-RealRisks,
and 1.94 at 6months, p < 0.01 for both comparisons).
Breast cancer worry and self-efficacy in chemoprevention
decision making did not change significantly. However,
decision conflict increased from post-intervention to 6
months (17.92 vs. 43.44, p < .01). After exposure to Real-
Risks, 23 women (64%) experienced some or no decisional
conflict with scores below 25 compared with 9 women
(28%) at 6months. Sub-scores for every decisional conflict
domain were in the same direction, with significantly
higher scores at 6months compared to post-intervention.
In terms of chemoprevention intention, 24% of partici-
pants expressed interest in taking chemoprevention, 47%
were unsure, and 29% were not interested. Three (7.5%)
women were referred for high-risk consultation and none
had initiated chemoprevention at 6months. There were
no significant differences in patient-reported outcomes
between Hispanic and non-Hispanic women, except that
Hispanic women tended to have higher mean breast
cancer worry scores (4.72 vs. 2.09 at baseline, 5.02 vs.
2.50 post-RealRisks, and 4.82 vs. 2.11 at 6 months,
respectively).
Discussion
Our intervention demonstrated a significant improve-
ment in accuracy of breast cancer risk perception and
an increase in chemoprevention knowledge. It was not-
able that accuracy of breast cancer risk perceptions
significantly improved post RealRisks, and was sustained
at 6 months. The finding that decision conflict signifi-
cantly increased from post-intervention to 6 months or
after clinical encounters with PCPs was unexpected. The
literature is not clear on why the decision to accept or
reject chemoprevention would become more difficult
with the passage of time. Possible explanations may res-
ide with the decision itself, the care pathway when the
DA was introduced, or a combination of both.
Decision conflict is not simply recognition that advan-
tages and disadvantages exist for any given option. It is
also an undesirable state of discomfort and internal con-
flict experienced when facing a difficult decision [38].
The decision to take chemoprevention can raise an un-
desirable state of discomfort given the perception that
SERMs or AIs are “cancer drugs” and tradeoffs between
the risks and benefits of these medications. It has been
proposed that the side effect profile of chemoprevention
medications, coupled with wide-ranging concerns about
the emotional impact of taking a medication, leads to
medication avoidance. Specifically, women might decide
to avoid chemoprevention because of the affect-laden re-
sponses associated with the term “side effect” and their
belief that these medications will increase, rather than
decrease, their level of health-related stress [39]. [40–42]
Concerns about possible side effects, such as uterine
cancer, thromboembolism, and menopausal symptoms,
are the primary reasons why women are reluctant to
start breast cancer chemoprevention [43–49]. This may
also explain results found in previous studies that im-
proved knowledge may result in women becoming more
reluctant to take medications that are associated with
potentially harmful health risks [14, 50].
It is recognized that negative emotions experienced
while making a choice involving difficult tradeoffs can
potentially impact decision conflict over time. The judg-
ment and decision-making literature suggests that
people can react to emotionally laden decisions by alter-
ing the amount or content of thought about the decision
(emotion-focused coping). This can result in avoidant
behaviors, for example declining to make a decision
[51], allowing another make the decision for you, or
exhibiting an increased tolerance for the status quo op-
tion [52]. Studies suggest that decision makers are likely
to face between attribute tradeoffs required by decision
conflict when the attributes are relatively low in emo-
tional tradeoff difficulty. Conversely, they tend to elude
these tradeoffs when attributes are higher in emotional
tradeoff difficulty. Thus, it is plausible that increased
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Table 1 Baseline characteristics of high-risk women identified during screening mammography, Columbia University Medical Center
(CUMC), New York, NY (Mar 2016-Sept 2016) stratified by Hispanic and non-Hispanic ethnicity
Patient Characteristics Hispanics (N = 17) Non-Hispanics (N = 23) Total (N = 40) p-value
Age, years, N (%) 0.57
< 50 2 (11.8) 0 2 (5.0)
50–59 1 (5.9) 4 (17.4) 5 (12.5)
60–69 10 (58.8) 14 (60.9) 24 (60.0)
> 70 4 (23.5) 5 (21.7) 9 (22.5)
Median (range) 64 (49–72) 66 (50–72) 64.5 (49–72)
Mean (SD) 63.1 (7.2) 64.3 (6.5) 63.8 (6.7)
Menopausal status, N (%) 0.17
Premenopausal/Perimenopausal 2 (11.8) 0 2 (5.0)
Postmenopausal 15 (88.2) 23 (100.0) 38 (95.0)
Race/ethnicity, N (%) N/A
Hispanic 17 (100.0) 0 17 (42.5)
Non-Hispanic white 0 16 (69.6) 16 (40.0)
Non-Hispanic black 0 5 (21.7) 5 (12.5)
Other 0 2 (8.7) 2 (5.0)
Education level, N (%) < 0.01
High school or less 11 (64.7) 1 (4.3) 12 (30.0)
Some college or bachelors 4 (23.5) 11 (47.8) 15 (37.5)
Graduate or professional degree 2 (11.8) 11 (47.8) 13 (32.5)
Benign breast disease, N (%) 7 (41.2) 7 (30.4) 14 (35.0) 0.75
First-degree family history of breast cancer, N (%) 12 (70.6) 8 (34.8) 20 (50.0) 0.05
5-year invasive breast cancer risk, % 0.45
Median (range) 2.01 (1.68–5.64) 2.23 (1.70–4.55) 2.19 (1.68–5.64)
Mean (SD) 2.26 (0.92) 2.46 (0.72) 2.38 (0.81)
Lifetime invasive breast cancer risk, % 0.57
Median (range) 7.87 (5.25–23.85) 8.85 (4.42–14.14) 8.71 (4.42–23.85)
Mean (SD) 9.88 (4.99) 9.10 (2.97) 9.43 (3.92)
Age of menarche, N (%) 0.02
7–11 years 1 (5.9) 8 (34.8) 9 (22.5)
12–13 years 11 (64.7) 14 (60.9) 25 (62.5)
14+ years 5 (29.4) 1 (4.3) 6 (15.0)
Age of first birth, N (%) 0.17
No births 1 (5.9) 2 (8.7) 3 (7.5)
< 20 years 4 (23.5) 4 (17.4) 8 (20.0)
20–24 years 4 (23.5) 3 (13.0) 7 (17.5)
25–29 years 4 (23.5) 1 (4.3) 5 (12.5)
30+ years 4 (23.5) 13 (56.5) 17 (42.5)
Hormone replacement therapy use 2 (11.8) 4 (17.4) 6 (15.0) 0.93
Mean acculturation (SD) [range, 1–5] 1.36 (0.56) 4.89 (0.26) 3.40 (1.81) <.01
Adequate health literacy, N (%) 11 (64.7) 22 (95.7) 33 (82.5) 0.03
Mean subjective numeracy (SD) [range, 1–6] 3.22 (0.19) 4.54 (0.67) 4.05 (0.95) <.01
Adequate numeracy, N (%) 6 (35.3) 19 (82.6) 25 (62.5) <.01
Mean Confidence (SD) [range, 1–10] 9.48 (0.87) 8.95 (1.61) 9.18 (1.36) 0.20
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decision conflict from post intervention to 6 months was
due to decision avoidance, given that the decision to
take chemoprevention requires women to evaluate a
number of emotionally laden tradeoffs, mainly between
the potential benefits and perceived barriers to chemo-
prevention medication uptake [53].
As previously asserted in the literature, it is mostly ac-
ceptable for decisional conflict to be high if measured
shortly after options have been presented, however after
the patient has been given the opportunity to incorpor-
ate their preferences into the presented options and
make a decision, decisional conflict should be low [54].
An equally plausible assertion is that for a patient who
prudently weighs competing options decision conflict
will be high and even with the passage of time, a rational
patient would state that the decision was difficult [55,
56]. Few randomized controlled trials have investigated
timed measurements of decision conflict, particularly in
underserved populations. Our conclusions are limited
due to study design and the lack of a control group in
our pilot study, however this area warrants further
investigation.
With respect to care pathway, although we tried to inte-
grate the web-based patient and provider decision support
tools into clinic workflow, use of the RealRisks DA was
not closely linked with the PCP clinical encounter. Many
of the patient-reported outcomes, such as accurate breast
cancer risk perceptions and chemoprevention knowledge,
diminished from immediately post-intervention to 6
months or after the clinical encounter. The increase in
decision conflict may also reflect a diminished patient out-
come since significantly fewer women were in the decision
Table 2 Patient-reported outcomes at baseline, post-intervention (RealRisks) and at 6 months or after the clinical encounter with
their primary care providers
Patient Outcome Measures Baseline (T0) Post-RealRisks (T1) Post-Clinical Encounter
or 6 months (T2)
p-value
(N = 40) (N = 37) (N = 32) T0-T1 T0-T2 T1-T2
Breast Cancer Risk Perception
Mean difference between perceived and actual
lifetime breast cancer risk (SD)
23.67 (24.68) 12.09 (18.13) 20.35 (27.65) 0.01 0.36
Accurate breast cancer risk perception, N(%) 15 (39.47) 23 (63.89) 20 (62.50) 0.02 0.02
Breast cancer knowledge
Mean number correct (SD) [range, 0–15] 8.00 (1.69) 8.59 (1.38) 7.94 (1.90) 0.10 0.14
Adequate knowledge, N (%) 25 (64.10) 30 (81.08) 17 (53.13) 0.13 .32
Chemoprevention knowledge
Mean number correct (SD) [range, 0–8] 0.71 (1.46) 3.69 (2.39) 1.94 (1.92) <.01 <.01
Adequate knowledge, N (%) 4 (10.53) 18 (50.00) 9 (28.13) < 0.01 0.10
Mean breast cancer worry (SD) [range, 1–7] 3.17 (1.80) 3.66 (2.17) 3.30 (2.06) 0.17 0.75
Mean self-efficacy in chemoprevention (SD)
[range, 0–100]
56 (15.81) 60.22 (15.45) 0.24
Mean decision conflict (SD) [range, 0–100] 17.92 (19.51) 43.44 (31.30) <.01
Decision conflict, N (%) <.01
Decision implementation (< 25) 23 (63.9) 9 (28.1)
Unsure about implementation (25–37.5) 5 (13.9) 5 (15.6)
Decision delay (> 37.5) 8 (22.2) 18 (56.3)
Decision conflict sub-scores (SD) (range, 0–100)
Informed subscore 9.03 (12.66) 24.48 (19.74) <.01
Values clarity subscore 8.33 (15.24) 23.44 (20.02) <.01
Support subscore 7.87 (9.33) 17.71 (18.66) 0.01




High-risk referrals, N (%) 3 (7.5)
Chemoprevention uptake, N (%) 0
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implementation phase according to the DCS. Nearly a
quarter of women expressed interest in chemoprevention
uptake after completing RealRisks, yet few women were
referred for high-risk consultations and none of the partic-
ipants had initiated chemoprevention at 6months. Per-
haps linking use of the DA more proximally to the clinical
encounter will improve our patient reported outcomes. In
future work, we have incorporated alerts and other cues
to remind the patient to complete the RealRisks DA
within a week prior to the clinical encounter.
Similar to previous studies, our intervention demon-
strated that decision aids improve knowledge in those
who use them. However, also like previous studies, in-
creased knowledge does not lead to increased chemopre-
vention uptake for the purpose of reducing breast cancer
risk. Improved accuracy of risk perceptions is an import-
ant measure of the quality of a decision aid [57], and
while this is a prerequisite to informed decision making,
it is difficult to know if this results in clinically useful de-
cision making. Even when breast cancer risk seems to be
understood, willingness to take chemoprevention medi-
cation remains low among women who are identified as
eligible based on their Gail risk score [14, 58]. Previous
research has demonstrated that health decision making
may be based on heuristics and feelings, rather than on
an accurate understanding of risk information [59, 60].
As such, individuals may not always process and act
upon the risk information presented to them in the ways
that healthcare providers intend. In addition to precise
probabilistic risk information, lived experiences and par-
ticularly individual experiences with cancer have been
shown to influence chemoprevention decisions [58, 61].
Several studies have demonstrated that recommenda-
tions from physicians and effective communication
greatly affect patients’ decision making in chemopreven-
tion uptake [43]. Based upon data from key informant
interviews, we found that PCPs reveal unfamiliarity with
breast cancer risk assessment tools such as the Gail
Model and a lack of confidence in prescribing chemo-
prevention. PCPs also reveal a preference to refer their
patients to specialists for consultation about breast can-
cer risk reduction options, which may imply that the
they were not well-informed about breast cancer pre-
ventive strategies available to patients [25]. Although all
high-risk women and PCPs were given information on
the CUMC breast clinic for high-risk consultations, it
appears this was insufficient to alter practice patterns for
most PCPs.
Trials of decision support tools designed to increase
uptake of breast cancer chemoprevention targeting both
patients and providers have been limited. Uptake re-
mains low [14], [15] and as demonstrated in a random-
ized controlled trial of the BreastCARE intervention
discussions about chemoprevention were still limited
[16]. This prior literature suggests that just targeting
high-risk women or PCPs alone is ineffective. Additional
work remains to better understand the impact of deci-
sion aids targeting both patients and providers.
Limitations
Limitations of our study include the lack of a concurrent
control arm, the relatively small sample size, and con-
ducting the study in an urban academic center with ac-
cess to a high-risk clinic, all of which limit the
generalizability of our findings. In addition, although we
found no significant differences in age, race, and racial
distribution between the pilot sample and KYRAS
high-risk patients, our sample was self-selected from the
larger KYRAS screening study. The study sample was
older than what we expected and may not be totally rep-
resentative of a higher risk younger population who are
likely more appropriate for chemoprevention and the
RealRisks DA. Additionally, we had higher than antici-
pated loss to follow-up of about 20%. Our short-term
follow-up of 6 months may have been insufficient to as-
sess clinical outcomes such as high-risk clinic referrals
and actual chemoprevention uptake.
Conclusions
We developed decision support tools for both patients
and their PCPs, which include personalized risk reports
and education about breast cancer risk and chemopre-
vention. Our study population was racially and ethnically
diverse and our patient-centered DA, which is available
in English and Spanish, was rigorously tested in women
of multiple ethnicities with varying levels of health
literacy and numeracy. In addition to using validated
outcome measures, we were able to assess referrals to
the high risk breast clinic and actual chemoprevention
uptake using electronic health records.
The results of our initial pilot study have informed the
design and conduct of a larger randomized controlled
trial of 300 high-risk women assigned to standard educa-
tional materials alone or in combination with RealRisks
and BNAV (NCT03069742). We will target younger,
healthier women with higher breast cancer risk, includ-
ing those with high-risk benign breast lesions such as
atypical hyperplasia and lobular carcinoma in situ. These
women are likely to derive a greater benefit from breast
cancer risk reduction and a lower risk of serious side ef-
fects. To reinforce use of the patient-centered RealRisks
DA, we will set up automated reminders to revisit the
tool prior to their next PCP clinical encounter, next
screening mammography visit, and birthday (as breast
cancer risk increases with advancing age). We will en-
hance provider engagement with an enhanced BNAV
tool, which will offer continuing medical education
(CME) credit and additional modules on breast cancer
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screening and other topics relevant to PCPs. We have
already developed modules on risk communication and
shared decision making. We will elicit patient prefer-
ences for chemoprevention, specifically factors that are
most important and least important to chemoprevention
decisions, which we will summarize for providers prior
to the clinical encounter. Even if we do not observe a
significant increase in chemoprevention uptake with the
addition of RealRisks and BNAV compared to standard
educational materials, our goal is to also increase in-
formed choice, decrease decision conflict, and facilitate
SDM during the clinical encounter. Facilitating discus-
sions about breast cancer chemoprevention between cli-
nicians and high-risk women is in accordance with
recommendations from the U.S. Preventive Services
Task Force (USPSTF), American Society for Clinical On-
cology (ASCO), National Comprehensive Cancer Net-
work (NCCN), and the National Institute for Health and
Care Excellence (NICE) [8–11].
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